Compass Pathways/$CMPS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Compass Pathways
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
Ticker
$CMPS
Sector
Primary listing
Employees
156
Headquarters
Website
Compass Pathways Metrics
BasicAdvanced
$1.3bn
-
-$3.08
2.02
-
Price and volume
Market cap
$1.3bn
Beta
2.02
52-week high
$10.21
52-week low
$2.25
Average daily volume
4.5m
Financial strength
Current ratio
0.773
Quick ratio
0.666
Long term debt to equity
-29.144
Total debt to equity
-66.294
Interest coverage (TTM)
-38.81%
Profitability
EBITDA (TTM)
-175.074
Effective tax rate (TTM)
0.85%
Management effectiveness
Return on assets (TTM)
-51.68%
Return on equity (TTM)
-565.28%
Valuation
Price to book
-18.02
Price to tangible book (TTM)
-18.02
Price to free cash flow (TTM)
-5.893
Free cash flow yield (TTM)
-16.97%
Free cash flow per share (TTM)
-1.682
Growth
Earnings per share change (TTM)
33.93%
3-year earnings per share growth (CAGR)
12.60%
What the Analysts think about Compass Pathways
Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.
Compass Pathways Financial Performance
Revenues and expenses
Compass Pathways Earnings Performance
Company profitability
Compass Pathways News
AllArticlesVideos
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
Business Wire·6 days ago
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·6 days ago
These 3 Psychedelic Stocks Activated After Trump's Executive Order
MarketBeat·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Compass Pathways stock?
Compass Pathways (CMPS) has a market cap of $1.3B as of May 12, 2026.
What is the P/E ratio for Compass Pathways stock?
The price to earnings (P/E) ratio for Compass Pathways (CMPS) stock is 0 as of May 12, 2026.
Does Compass Pathways stock pay dividends?
No, Compass Pathways (CMPS) stock does not pay dividends to its shareholders as of May 12, 2026.
When is the next Compass Pathways dividend payment date?
Compass Pathways (CMPS) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Pathways?
Compass Pathways (CMPS) has a beta rating of 2.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.